Bone Biologics Corp Warrants
BBLGW
2 hedge funds and large institutions have $324K invested in Bone Biologics Corp Warrants in 2023 Q3 according to their latest regulatory filings, with 2 funds opening new positions, increasing their positions, 0 reducing their positions, and 1 closing their positions.
40,203% more capital invested
Capital invested by funds: $805 → $324K (+$324K)
100% more funds holding
Funds holding: 1 → 2 (+1)
100% more first-time investments, than exits
New positions opened: 2 | Existing positions closed: 1
0.77% more ownership
Funds ownership: 0% → 0.78% (+0.77%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Citadel Advisors
Miami,
Florida
|
+$119K |
| 2 |
UBS Group
Zurich,
Switzerland
|
+$299 |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
CS
Clear Street
New York
|
-$802 |
BBLGW Hedge Fund Activity: Q3 2023 in Review
2 of the 6,312 institutional investors tracked by Wall St. Rank reported a position in Bone Biologics Corp Warrants (BBLGW) for Q3 2023, worth a combined $324K — up 40,203% from $805 a quarter earlier.
Buyers outnumbered sellers: 2 funds opened new BBLGW positions and 1 closed out — a net gain of 1 holder — while 0 added to existing stakes and 0 trimmed.
The largest buyer was Citadel Advisors, opening a new position worth an estimated $119K. The largest seller was Clear Street, exiting entirely with an estimated $802 sold.
- 2 institutional investors held Bone Biologics Corp Warrants (BBLGW) as of Q3 2023, up from 1 in Q2 2023.
- Funds reported $324K of Bone Biologics Corp Warrants stock for Q3 2023, up 40,203% quarter-over-quarter.
- 2 funds opened new Bone Biologics Corp Warrants positions in Q3 2023 and 1 closed out, a net change of +1 holder.
- The largest Bone Biologics Corp Warrants buyer in Q3 2023 was Citadel Advisors, an estimated $119K added.
- The largest Bone Biologics Corp Warrants seller in Q3 2023 was Clear Street, an estimated $802 sold.
Based on aggregated 13F filings for Q3 2023.